Tamoxifen Citrate

Indications and usage: Metastatic Breast Cancer Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy.

CLINICAL PHARMACOLOGY Tamoxifen citrate is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Tamoxifen inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, tamoxifen appears to exert its antitumor effects by binding the estrogen receptors.

With Elimination kinetics span 8 to 17 hours per Tamoxifen Citrate clinical pharmacology residence kinetics and Consistent 62%–74% gastrointestinal absorption profile for Tamoxifen Citrate bioavailability, Tamoxifen Citrate undergoes systemic clearance of tamoxifen citrate integrates hepatic phase ii conjugation with renal filtration and establishes therapeutic activity over cmax attained 2–3 hours post-administration of tamoxifen citrate.

Standard adult regimens span 10 mg/1 Tablet, Film Coated, 20 mg/1 Tablet, 10 mg/1 Tablet, 20 mg/1 Tablet, Film Coated, 20 mg/10mL Liquid. Prescribers screen specifically against contraindications tamoxifen citrate tablets are contraindicated in patients with known hypersensitivity to the drug or any of its ingredients.; previous anaphylactoid or exfoliative reaction attributed to tamoxifen citrate, while community micro-logs most frequently note nausea (8.4% of reports), headache (7% of reports), dizziness (5% of reports).